Appl. No. : 10/828,795 Filed : April 21, 2004

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

- 1-7. (CANCELED)
- 8. (CURRENTLY AMENDED) The composition of claim 1, A composition for affecting weight loss comprising a first compound and a second compound, wherein said first compound is naltrexone, or a pharmaceutically acceptable salt or prodrug thereof, and said second compound is fluoxetine bupropion, or a pharmaceutically acceptable salt or prodrug thereof.
- 9. (CURRENTLY AMENDED) The composition of claim 4 8, wherein said first compound is naltrexone and said second compound is bupropion.
- 10. (CURRENTLY AMENDED) A method of affecting weight loss, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance α-MSH activity with a composition comprising a first compound and a second compound, wherein said first compound is naltrexone, or a pharmaceutically acceptable salt or prodrug thereof, and wherein said second compound is bupropion, or a pharmaceutically acceptable salt or prodrug thereof.
- 11. (ORIGINAL) The method of claim 10, wherein said individual has a body mass index greater than 25.
 - 12-18. (CANCELED)
- 19. (CURRENTLY AMENDED) The method of claim 18 10, wherein said first compound and said second compound are administered nearly simultaneously.
 - 20-21. (CANCELED)
- 22. (NEW) The method of claim 10, wherein said first compound is administered prior to said second compound.
- 23. (NEW) The method of claim 10, wherein said first compound is administered subsequent to said second compound.
- 24. (NEW) The method of claim 10, wherein said individual is not suffering from depression.
- 25. (NEW) The method of claim 10, wherein said first compound is naltrexone and said second compound is bupropion.

Appl. No. : 10/828,795 Filed : April 21, 2004

- 26. (NEW) A method of increasing satiety in an individual comprising identifying an individual in need thereof and treating that individual with a composition comprising a first compound and a second compound, wherein said first compound is naltrexone, or a pharmaceutically acceptable salt or prodrug thereof, and wherein said second compound is bupropion, or a pharmaceutically acceptable salt or prodrug thereof.
- 27. (NEW) The method of claim 26, wherein said first compound is administered prior to said second compound.
- 28. (NEW) The method of claim 26, wherein said first compound is administered subsequent to said second compound.
- 29. (NEW) The method of claim 26, wherein said individual is not suffering from depression.
- 30. (NEW) The method of claim 26, wherein said first compound is naltrexone and said second compound is bupropion.
- 31. (NEW) A method of suppressing the appetite of an individual comprising identifying an individual in need thereof and treating that individual with a composition comprising a first compound and a second compound, wherein said first compound is naltrexone, or a pharmaceutically acceptable salt or prodrug thereof, and wherein said second compound is bupropion, or a pharmaceutically acceptable salt or prodrug thereof.
- 32. (NEW) The method of claim 31, wherein said first compound is administered prior to said second compound.
- 33. (NEW) The method of claim 31, wherein said first compound is administered subsequent to said second compound.
- 34. (NEW) The method of claim 31, wherein said individual is not suffering from depression.
- 35. (NEW) The method of claim 31, wherein said first compound is naltrexone and said second compound is bupropion.
- 36. (NEW) A pharmaceutical composition comprising a first compound, a second compound, and a pharmaceutically acceptable excipient, diluent, or carrier, wherein said first compound is naltrexone, or a pharmaceutically acceptable salt or prodrug thereof, and

Appl. No. : 10/828,795 Filed : April 21, 2004

wherein said second compound is bupropion, or a pharmaceutically acceptable salt or prodrug thereof.

37. (NEW) The pharmaceutical composition of claim 36, wherein said first compound is naltrexone and said second compound is bupropion.